BrainsWay (NASDAQ:BWAY) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of BrainsWay (NASDAQ:BWAY) in a research note published on Monday, Benzinga reports. They currently have a $16.00 price objective on the stock.

Separately, Northland Securities upped their price target on shares of BrainsWay from $9.00 to $11.00 and gave the stock an outperform rating in a research note on Wednesday, August 7th.

BrainsWay Stock Performance

Shares of NASDAQ BWAY opened at $8.19 on Monday. The company has a 50 day simple moving average of $7.44 and a two-hundred day simple moving average of $6.34. BrainsWay has a fifty-two week low of $3.09 and a fifty-two week high of $8.75. The company has a market capitalization of $136.49 million, a price-to-earnings ratio of -91.00 and a beta of 1.25.

BrainsWay (NASDAQ:BWAY) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.04 earnings per share for the quarter. BrainsWay had a return on equity of 1.45% and a net margin of 1.67%. The company had revenue of $10.01 million during the quarter, compared to analyst estimates of $9.40 million. During the same quarter last year, the company earned ($0.05) EPS. On average, analysts forecast that BrainsWay will post 0.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BrainsWay

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BWAY. Essex Investment Management Co. LLC raised its stake in shares of BrainsWay by 37.5% in the first quarter. Essex Investment Management Co. LLC now owns 324,843 shares of the company’s stock worth $1,718,000 after purchasing an additional 88,593 shares during the last quarter. Acadian Asset Management LLC increased its holdings in BrainsWay by 48.1% in the 2nd quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock worth $1,567,000 after buying an additional 84,371 shares in the last quarter. Jump Financial LLC purchased a new position in BrainsWay in the 4th quarter worth about $207,000. Perritt Capital Management Inc bought a new position in BrainsWay during the 2nd quarter valued at about $121,000. Finally, Rhumbline Advisers boosted its holdings in shares of BrainsWay by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after acquiring an additional 1,695 shares during the last quarter. 30.11% of the stock is owned by institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.